Pfizer – Talk Bio

HHS ousts MAHA implementation lead amid rushed cancellations of $500M in mRNA vaccine contracts

2 weeks ago talkbio0Tagged BARDA, CHARGE Syndrome, Contract agreement, Gray Delany, MAHA, Moderna, mRNA contracts, Pfizer, Policy, Robert F. Kennedy, Seqirus, Shakeup, SMPX gene, Staff, terminations, Vaccines

HHS; MAHA; Gray Delany; mRNA contracts; BARDA; Robert F. Kennedy Jr.; vaccine policy; contract terminations; Moderna; Pfizer; CSL Seqirus; staff shakeup

GSK set to receive over $500M from mRNA patent settlement tied to BioNTech–CureVac–Pfizer deal

2 weeks ago talkbio0Tagged BioNTech, BioNTech acquisition, COVID19 (disease), CureVac, global framework, Influenza virus vaccine, Licensing, Litigation, Pfizer, RNA, Messenger, royalties, settlement, SmithKline Beecham, U.S., upfront payment, Vaccines, Vaccines, Combined

GSK; CureVac; BioNTech; Pfizer; mRNA patents; settlement; royalties; COVID-19 vaccine; influenza vaccine; combination vaccines; licensing; upfront payment; US litigation; global framework; BioNTech acquisition of CureVac

HHS Cancels $500 Million in BARDA-Funded mRNA Vaccine Contracts Amid Strategic Shift

3 weeks ago talkbio0Tagged BARDA, CHARGE Syndrome, contract cancellation, COVID19 (disease), development aspects, federal funding, Moderna, mRNA Vaccine, Pfizer, Robert F. Kennedy Jr., Seqirus, Vaccines

HHS; BARDA; mRNA vaccine; vaccine development; contract cancellation; Robert F. Kennedy Jr.; COVID-19; federal funding; Moderna; Pfizer; Seqirus

Pfizer’s Embattled Obesity Program Loses Another GLP-1 Drug Due to Data and Competition Issues

3 weeks ago talkbio0Tagged Agonist, Clinical Trials, competition, Danuglipron, Drug Development, Glucagon-Like Peptide 1, Injury of liver, lotiglipron, Obesity, PF-06954522, Pfizer

Pfizer; obesity; GLP-1 agonist; clinical trial; liver injury; danuglipron; lotiglipron; PF-06954522; obesity drug development; competition

Pfizer CEO Holds ‘Extremely Productive’ Talks With Trump Administration Amid MFN Pricing and Tariff Threats

3 weeks ago talkbio0Tagged Albert Bourla, Direct-to-Consumer, Drug Industry, drug price, Jr., Mehmet, Nation, negotiation, ounce, Pfizer, PhRMA, Policy, Pricing, Robert F. Kennedy, tariffs, Trump administration

Pfizer; Albert Bourla; Trump administration; Most Favored Nation (MFN) pricing; drug pricing; tariffs; pharmaceutical industry; direct-to-consumer (DTC) sales; policy negotiation; Robert F. Kennedy Jr.; Mehmet Oz; PhRMA

Moderna Wins UK Appeals Court in Covid-19 Patent Case Against Pfizer/BioNTech

3 weeks ago talkbio0Tagged appeal, BioNTech, court, COVID19 (disease), EP'949, infringement, Legal patent, legal victory, Moderna, Pfizer, UK, Vaccines

Moderna; Pfizer; BioNTech; UK Court of Appeal; COVID-19 vaccine; patent infringement; EP’949 patent; Comirnaty; legal victory

Bristol Myers Squibb and Pfizer Launch Direct-to-Consumer Discount Program for Eliquis

1 month ago talkbio0Tagged Anticoagulants, blood thinner, Direct-to-Consumer, Eliquis, Myers, online program, Pfizer, squibb

Bristol Myers Squibb; Pfizer; Eliquis; direct-to-consumer; discount; online program; Eliquis 360 Support; anticoagulant; blood thinner; patient access

Pfizer Warns of ‘Near-Term Stock Out’ of Penicillin Used for Treating Syphilis in Pregnant Women After Recall

1 month ago talkbio0Tagged Bicillin L-A, Drug Shortage, Extencilline, penicillin recall, Pfizer, Pregnant Women, public health medicine (field), syphilis treatment, Syphilis, Congenital, United States Food and Drug Administration

Pfizer; penicillin recall; Bicillin L-A; syphilis treatment; pregnant women; drug shortage; congenital syphilis; FDA; Extencilline; public health

Pfizer, Astellas’ Xtandi Combo Extends Survival in Early Prostate Cancer

1 month ago talkbio0Tagged Astellas, BCR, biochemical recurrence, Combined Modality Therapy, EMBARK, enzalutamide, leuprolide, Malignant neoplasm of prostate, nmHSPC, non-metastatic, Overall Survival, Pfizer, Xtandi

Pfizer; Astellas; Xtandi; Enzalutamide; prostate cancer; overall survival; combination therapy; leuprolide; non-metastatic hormone-sensitive prostate cancer (nmHSPC); EMBARK study; biochemical recurrence (BCR)

Axsome Plots New Fibromyalgia Trial After FDA Refuses Review of Former Pfizer Candidate

2 months ago talkbio0Tagged Analgesics, AXS-14, Axsome, Clinical Trials, esreboxetine, Fibromyalgia, File (record), Pfizer, refusal, trial design, United States Food and Drug Administration

Axsome Therapeutics; esreboxetine; fibromyalgia; FDA; refusal to file; clinical trial; Pfizer; AXS-14; trial design; pain medicine